CSRxP Calls for Further Action on Rx Prices

CSRxP spokesman Will Holley releases statement following House passage of FDA user fee legislation.

Read more

CSRxP Highlights Big Pharma’s Price Gouging Tactics With New Spot: “The Right”

“The Right” highlights examples of Big Pharma’s price-gouging tactics, such as Miacalcin’s 3,200% price hike, Daraprim’s 5,000% price hike, and doxycycline’s 9,000% price increase in just six months. These price hikes are part of a longstanding pattern that show no sign of slowing down – in fact, a recent report showed that there were more price hikes in the first quarter of 2017 than there were in the first quarter of 2016.

Read more

CSRxP Rolls Out Latest Ad: “Priorities”

It’s time for Big Pharma to get their priorities straight: American’s deserve open and honest prescription drug pricing.

Read more

Avik Roy Unveils “The Competition Prescription”

Read “The Competition Prescription,” a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down.

Read more